NCT05139095 2026-02-05
Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia
Peking Union Medical College Hospital
Phase 2 Recruiting
Clinical Trials
19 trialsNCT06561308 2025-12-01
Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer
Women's Hospital School Of Medicine Zhejiang University
Phase 2 Recruiting
NCT07143292 2025-11-18
A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT04680988 2025-08-05
A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT06288360 2025-03-20
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
Tongji Hospital
Phase 2 Recruiting
NCT06289062 2024-11-05
Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer
Tongji Hospital
Phase 2 Recruiting
NCT06413992 2024-05-14
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT03816553 2023-04-11
SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer
Sun Yat-sen University
Phase 2 Completed
NCT05550558 2022-09-28
CAN-RESPOND
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT03827837 2022-07-01
Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT04812002 2022-06-03
Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy
Women's Hospital School Of Medicine Zhejiang University
Phase 2 Recruiting
NCT05311566 2022-04-13
PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05151549 2021-12-09
A Study of Carilizumab Combined With Concurrent Chemoradiotherapy
Hunan Cancer Hospital
Phase 2 Unknown
NCT04974944 2021-10-01
First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT04974827 2021-08-10
A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer
Hunan Cancer Hospital
Phase 2 Unknown
NCT04047017 2021-07-30
GTN
Peking Union Medical College Hospital
Phase 2 Completed
NCT04884906 2021-05-13
Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04068974 2021-03-16
Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04239443 2020-01-27
Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer
Hunan Cancer Hospital
Phase 2 Unknown